World’s First Lung Cancer Vaccine has Entered Clinical Trials in seven countries
The world’s first lung cancer vaccine enters clinical trials, It aims to revolutionize treatment for millions globally
Seven countries, including the UK, US, and Germany, are participating 130 patients are enrolled across 34 centers
The UK’s UCLH administered the first vaccine dose, It marked the official start of this pioneering trial
The vaccine uses BioNTech’s mRNA platform, It trains the immune system to attack cancer cells
Researchers are evaluating safety and immune response. Some patients will get it alongside standard therapies
Focus is on non-small cell lung cancer (NSCLC), NSCLC is the most common and deadliest lung cancer
This vaccine may prevent relapse or progression, Experts see it as a leap toward personalized cancer care
If successful, it will advance to Phase II/III soon, Wider use could transform standard cancer treatment